Cargando…

Characterization and risk factors of hyperglycaemia during treatment of childhood hematologic malignancies

BACKGROUND: Secondary forms of diabetes are often understudied and underdiagnosed in children and adolescents with cancer. The objectives of our cohort study were to study the incidence and risk factors for hyperglycaemia in leukaemia and lymphoma patients. METHODS: We retrospectively collected 15 y...

Descripción completa

Detalles Bibliográficos
Autores principales: Welsch, Sophie, Sawadogo, Kiswendsida, Brichard, Bénédicte, de Ville de Goyet, Maelle, Van Damme, An, Boulanger, Cécile, Lysy, Philippe A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9297930/
https://www.ncbi.nlm.nih.gov/pubmed/34652870
http://dx.doi.org/10.1111/dme.14720
_version_ 1784750584180506624
author Welsch, Sophie
Sawadogo, Kiswendsida
Brichard, Bénédicte
de Ville de Goyet, Maelle
Van Damme, An
Boulanger, Cécile
Lysy, Philippe A.
author_facet Welsch, Sophie
Sawadogo, Kiswendsida
Brichard, Bénédicte
de Ville de Goyet, Maelle
Van Damme, An
Boulanger, Cécile
Lysy, Philippe A.
author_sort Welsch, Sophie
collection PubMed
description BACKGROUND: Secondary forms of diabetes are often understudied and underdiagnosed in children and adolescents with cancer. The objectives of our cohort study were to study the incidence and risk factors for hyperglycaemia in leukaemia and lymphoma patients. METHODS: We retrospectively collected 15 years of data from paediatric patients treated for acute lymphoblastic leukaemia (ALL), Hodgkin's lymphoma (HL), and non‐Hodgkin's lymphoma (NHL) immediately at cancer diagnosis. We studied risk factors for hyperglycaemia in univariate and multivariate analyses. RESULTS: Our study cohort included 267 patients corresponding to 179 patients with ALL, 48 with NHL and 40 with HL. Eighteen per cent of ALL patients (32/179) and 17% of NHL patients (8/48) developed hyperglycaemia, with more than 61% developing hyperglycaemia within the first month of treatment. No hyperglycaemia was observed in HL patients. Multivariate analysis showed the following hyperglycaemia risk factors for ALL patients: overweight or obesity (OR 3.793) and pubertal onset (OR 4.269) at cancer diagnosis, steroid‐resistant disease (OR 3.445) and hematopoietic stem cell transplant (HSCT) (OR 4.754). CONCLUSION: In our cohort, 18% of patients with ALL or NHL developed early‐onset hyperglycaemia after chemotherapy/radiotherapy. Patients with ALL with increased hyperglycaemia risk can be readily identified by measuring BMI and puberty stage at cancer diagnosis. Also, glucose monitoring should be reinforced when patients show steroid‐resistant disease and/or require HSCT.
format Online
Article
Text
id pubmed-9297930
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-92979302022-07-21 Characterization and risk factors of hyperglycaemia during treatment of childhood hematologic malignancies Welsch, Sophie Sawadogo, Kiswendsida Brichard, Bénédicte de Ville de Goyet, Maelle Van Damme, An Boulanger, Cécile Lysy, Philippe A. Diabet Med Research: Complications BACKGROUND: Secondary forms of diabetes are often understudied and underdiagnosed in children and adolescents with cancer. The objectives of our cohort study were to study the incidence and risk factors for hyperglycaemia in leukaemia and lymphoma patients. METHODS: We retrospectively collected 15 years of data from paediatric patients treated for acute lymphoblastic leukaemia (ALL), Hodgkin's lymphoma (HL), and non‐Hodgkin's lymphoma (NHL) immediately at cancer diagnosis. We studied risk factors for hyperglycaemia in univariate and multivariate analyses. RESULTS: Our study cohort included 267 patients corresponding to 179 patients with ALL, 48 with NHL and 40 with HL. Eighteen per cent of ALL patients (32/179) and 17% of NHL patients (8/48) developed hyperglycaemia, with more than 61% developing hyperglycaemia within the first month of treatment. No hyperglycaemia was observed in HL patients. Multivariate analysis showed the following hyperglycaemia risk factors for ALL patients: overweight or obesity (OR 3.793) and pubertal onset (OR 4.269) at cancer diagnosis, steroid‐resistant disease (OR 3.445) and hematopoietic stem cell transplant (HSCT) (OR 4.754). CONCLUSION: In our cohort, 18% of patients with ALL or NHL developed early‐onset hyperglycaemia after chemotherapy/radiotherapy. Patients with ALL with increased hyperglycaemia risk can be readily identified by measuring BMI and puberty stage at cancer diagnosis. Also, glucose monitoring should be reinforced when patients show steroid‐resistant disease and/or require HSCT. John Wiley and Sons Inc. 2021-11-01 2022-02 /pmc/articles/PMC9297930/ /pubmed/34652870 http://dx.doi.org/10.1111/dme.14720 Text en © 2021 The Authors. Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Research: Complications
Welsch, Sophie
Sawadogo, Kiswendsida
Brichard, Bénédicte
de Ville de Goyet, Maelle
Van Damme, An
Boulanger, Cécile
Lysy, Philippe A.
Characterization and risk factors of hyperglycaemia during treatment of childhood hematologic malignancies
title Characterization and risk factors of hyperglycaemia during treatment of childhood hematologic malignancies
title_full Characterization and risk factors of hyperglycaemia during treatment of childhood hematologic malignancies
title_fullStr Characterization and risk factors of hyperglycaemia during treatment of childhood hematologic malignancies
title_full_unstemmed Characterization and risk factors of hyperglycaemia during treatment of childhood hematologic malignancies
title_short Characterization and risk factors of hyperglycaemia during treatment of childhood hematologic malignancies
title_sort characterization and risk factors of hyperglycaemia during treatment of childhood hematologic malignancies
topic Research: Complications
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9297930/
https://www.ncbi.nlm.nih.gov/pubmed/34652870
http://dx.doi.org/10.1111/dme.14720
work_keys_str_mv AT welschsophie characterizationandriskfactorsofhyperglycaemiaduringtreatmentofchildhoodhematologicmalignancies
AT sawadogokiswendsida characterizationandriskfactorsofhyperglycaemiaduringtreatmentofchildhoodhematologicmalignancies
AT brichardbenedicte characterizationandriskfactorsofhyperglycaemiaduringtreatmentofchildhoodhematologicmalignancies
AT devilledegoyetmaelle characterizationandriskfactorsofhyperglycaemiaduringtreatmentofchildhoodhematologicmalignancies
AT vandammean characterizationandriskfactorsofhyperglycaemiaduringtreatmentofchildhoodhematologicmalignancies
AT boulangercecile characterizationandriskfactorsofhyperglycaemiaduringtreatmentofchildhoodhematologicmalignancies
AT lysyphilippea characterizationandriskfactorsofhyperglycaemiaduringtreatmentofchildhoodhematologicmalignancies